<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62677">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02289963</url>
  </required_header>
  <id_info>
    <org_study_id>EFC14074</org_study_id>
    <secondary_id>U1111-1157-3294</secondary_id>
    <nct_id>NCT02289963</nct_id>
  </id_info>
  <brief_title>Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy in South Korea and Taiwan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by alirocumab as
      add-on therapy to stable maximally tolerated daily statin therapy with or without other
      lipid-modifying therapy (LMT) in comparison with placebo after 24 weeks of treatment in
      South Korea and Taiwan in high cardiovascular risk patients with hypercholesterolemia.

      Secondary Objectives:

        -  To evaluate the effect of alirocumab in comparison with placebo on LDL-C after 12 weeks
           of treatment.

        -  To evaluate the effect of alirocumab on other lipid parameters: apolipoprotein B (Apo
           B), non high density lipoprotein cholesterol (non-HDL-C), total cholesterol (TC),
           lipoprotein (a) (Lp [a]), high density lipoprotein cholesterol (HDL-C), triglycerides
           (TGs), and apolipoprotein A-1 (Apo A-1).

        -  To evaluate the safety and tolerability of alirocumab.

        -  To evaluate the development of anti-alirocumab antibodies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The maximum study duration will be 35 weeks per patient, including up to 3 weeks screening
      period, 24 weeks randomized treatment period, and 8 weeks follow-up period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percent change in calculated LDL-C from baseline to Week 24 in the intent-to-treat population</measure>
    <time_frame>From baseline to Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percent change in calculated LDL-C in the modified intent-to-treat population</measure>
    <time_frame>From baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percent change in calculated low density lipoprotein cholesterol (LDL-C)</measure>
    <time_frame>From baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percent change in apolipoprotein B (Apo B)</measure>
    <time_frame>From baseline to Week 24 and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percent change in non high density lipoprotein cholesterol (non-HDL-C)</measure>
    <time_frame>From baseline to Week 24 and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percent change in total cholesterol (TC)</measure>
    <time_frame>From baseline to Week 24 and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients reaching calculated LDL-C &lt;70 mg/dL (1.81 mmol/L)</measure>
    <time_frame>At Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percent change in lipoprotein a (Lp [a])</measure>
    <time_frame>From baseline to Week 24 and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percent change in high density lipoprotein cholesterol (HDL-C)</measure>
    <time_frame>From baseline to Week 24 and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percent change in fasting triglycerides (TGs)</measure>
    <time_frame>From baseline to Week 24 and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percent change in apolipoprotein A-1 (Apo A-1)</measure>
    <time_frame>From baseline to Week 24 and Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">199</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Alirocumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection through subcutaneous administration every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Injection through subcutaneous administration every 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alirocumab SAR236553/REGN727</intervention_name>
    <description>Pharmaceutical form:solution for injection Route of administration: subcutaneous</description>
    <arm_group_label>Alirocumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Pharmaceutical form:solution for injection Route of administration: subcutaneous</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Patients with hypercholesterolemia and established coronary heart disease (CHD) or CHD
        risk equivalents who are not adequately controlled with a maximally tolerated daily dose
        of statin with or without other LMT, both at stable dose for at least 4 weeks prior to
        screening visit (Week -3).

        Exclusion criteria:

        Aged &lt;18 years or legal age of adulthood, whichever is greater. Patients without
        established CHD or CHD risk equivalent. LDL-C &lt;70 mg/dL (&lt;1.81 mmol/L) in patients with a
        history of documented cardiovascular disease.

        LDL-C &lt;100 mg/dL (&lt;2.59 mmol/L) in patients without a history of documented cardiovascular
        disease.

        Not on a stable dose of LMT (including statin) for at least 4 weeks prior to the screening
        visit (Week -3) or between screening to randomization visits.

        Currently taking a statin other than atorvastatin, rosuvastatin or simvastatin.
        Atorvastatin, rosuvastatin or simvastatin is not taken daily or not taken at a registered
        dose.

        Daily doses above atorvastatin 80 mg, rosuvastatin 20 mg or simvastatin 40 mg. Fasting
        serum triglycerides &gt;400 mg/dL (&gt;4.52 mmol/L) at the screening period.

        The above information is not intended to contain all considerations relevant to a
        patient's potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 410009</name>
      <address>
        <city>Anyang-Si</city>
        <zip>431-070</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 410001</name>
      <address>
        <city>Anyang</city>
        <zip>431-070</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 410017</name>
      <address>
        <city>Busan</city>
        <zip>602-715</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 410007</name>
      <address>
        <city>Busan</city>
        <zip>614-735</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 410002</name>
      <address>
        <city>Daegu</city>
        <zip>700-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 410011</name>
      <address>
        <city>Goyang-Si</city>
        <zip>410-773</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 410003</name>
      <address>
        <city>Gwangju</city>
        <zip>501-757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 410012</name>
      <address>
        <city>Incheon</city>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 410018</name>
      <address>
        <city>Jeonju-Si</city>
        <zip>561-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 410006</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 410004</name>
      <address>
        <city>Seoul</city>
        <zip>07061</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 410015</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 410008</name>
      <address>
        <city>Seoul</city>
        <zip>110-746</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 410005</name>
      <address>
        <city>Seoul</city>
        <zip>134-727</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 410010</name>
      <address>
        <city>Seoul</city>
        <zip>152-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 410013</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 158007</name>
      <address>
        <city>Changhua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 158005</name>
      <address>
        <city>Hsinchu</city>
        <zip>30071</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 158011</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 158010</name>
      <address>
        <city>Kaohsiung</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 158006</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 158009</name>
      <address>
        <city>Tainan Hsien</city>
        <zip>710</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 158008</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 158001</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 158003</name>
      <address>
        <city>Taipei</city>
        <zip>104</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 158002</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 158004</name>
      <address>
        <city>Taoyuan Hsien</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 18, 2016</lastchanged_date>
  <firstreceived_date>November 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
